➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Mallinckrodt
McKinsey
Medtronic
McKesson

Last Updated: July 8, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GTx-024


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GTx-024?

GTx-024 is an investigational drug.

There have been 31 clinical trials for GTx-024. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Pancreatic Neoplasms, Prostatic Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are GTx, Columbia University, and National Cancer Institute (NCI).

There are forty US patents protecting this investigational drug and five hundred and thirty-eight international patents.

Recent Clinical Trials for GTx-024
TitleSponsorPhase
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeUltragenyx Pharmaceutical IncPhase 1/Phase 2
A Study of the Safety and Tolerability of GTX-102 in Children With Angelman SyndromeGeneTx Biotherapeuics, LLC.Phase 1/Phase 2
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary IncontinenceGTxPhase 2

See all GTx-024 clinical trials

Clinical Trial Summary for GTx-024

Top disease conditions for GTx-024
Top clinical trial sponsors for GTx-024

See all GTx-024 clinical trials

US Patents for GTx-024

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GTx-024   Start Trial SARMs and method of use thereof University of Tennessee Research Foundation (Knoxville, TN)   Start Trial
GTx-024   Start Trial Selective androgen receptor degrader (SARD) ligands and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) GTX, INC. (Memphis, TN)   Start Trial
GTx-024   Start Trial Selective androgen receptor degrader (SARD) ligands and methods of use thereof GTX, INC. (Memphis, TN)   Start Trial
GTx-024   Start Trial Selective androgen receptor modulator and methods of use thereof UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN)   Start Trial
GTx-024   Start Trial Methods of reducing mammographic breast density and/or breast cancer risk HAVAH THERAPEUTICS PTY LTD. (Stirling, South Australia, AU)   Start Trial
GTx-024   Start Trial Methods of reducing mammographic breast density and/or breast cancer risk HAVAH THERAPEUTICS PTY LTD. (Stirling, South Australia, AU)   Start Trial
GTx-024   Start Trial Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) GTx, Inc. (Memphis, TN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GTx-024

Drugname Country Document Number Estimated Expiration Related US Patent
GTx-024 Argentina 061980 2026-07-12   Start Trial
GTx-024 Argentina 062536 2026-07-12   Start Trial
GTx-024 Austria 344233 2020-08-24   Start Trial
GTx-024 Austria 423092 2020-08-24   Start Trial
GTx-024 Austria 430125 2020-08-24   Start Trial
GTx-024 Austria 526959 2020-08-24   Start Trial
GTx-024 Austria 533494 2020-08-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
Johnson and Johnson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.